Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring.
Publication
, Journal Article
Hussain, Z; Baldassarre, L; Dent, S; Weintraub, NL; Guha, A
Published in: Eur J Prev Cardiol
July 20, 2022
Duke Scholars
Published In
Eur J Prev Cardiol
DOI
EISSN
2047-4881
Publication Date
July 20, 2022
Volume
29
Issue
9
Start / End Page
1309 / 1311
Location
England
Related Subject Headings
- Thromboembolism
- Taiwan
- Risk Assessment
- Protein Kinase Inhibitors
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Humans
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Hussain, Z., Baldassarre, L., Dent, S., Weintraub, N. L., & Guha, A. (2022). Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring. Eur J Prev Cardiol, 29(9), 1309–1311. https://doi.org/10.1093/eurjpc/zwab055
Hussain, Zeeshan, Lauren Baldassarre, Susan Dent, Neal L. Weintraub, and Avirup Guha. “Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring.” Eur J Prev Cardiol 29, no. 9 (July 20, 2022): 1309–11. https://doi.org/10.1093/eurjpc/zwab055.
Hussain Z, Baldassarre L, Dent S, Weintraub NL, Guha A. Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring. Eur J Prev Cardiol. 2022 Jul 20;29(9):1309–11.
Hussain, Zeeshan, et al. “Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring.” Eur J Prev Cardiol, vol. 29, no. 9, July 2022, pp. 1309–11. Pubmed, doi:10.1093/eurjpc/zwab055.
Hussain Z, Baldassarre L, Dent S, Weintraub NL, Guha A. Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring. Eur J Prev Cardiol. 2022 Jul 20;29(9):1309–1311.
Published In
Eur J Prev Cardiol
DOI
EISSN
2047-4881
Publication Date
July 20, 2022
Volume
29
Issue
9
Start / End Page
1309 / 1311
Location
England
Related Subject Headings
- Thromboembolism
- Taiwan
- Risk Assessment
- Protein Kinase Inhibitors
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Humans
- 3201 Cardiovascular medicine and haematology